CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for biOasis Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

biOasis Technologies Inc
130-10691 Shellbridge Way
Phone: (604) 295-7014p:604 295-7014 RICHMOND, BC  V6X 2W8  Canada Ticker: BTIBTI

Business Summary
biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. The Company researches and develops products for diagnosis and treatment of neurological diseases and disorders. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB). The Transcend brain delivery platform exploits the BBB penetrating properties of a recombinant soluble human protein known as melanotransferrin (MTf or p97) and portions thereof. Transcend delivery molecules have the ability to transport a range of molecules across the BBB. The Company owns approximately 30 the United States and foreign patents/applications related to p97 as a BBB delivery vector and as a biomarker for Alzheimer's disease.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
8/31/20192/28/2019Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, President, Chief Executive Officer Deborah A.Rathjen 3/11/2019 9/21/2017
Chief Financial Officer ChristineAntalik 1/9/2019 1/9/2019
Chief Operating Officer CarolineDircks 8/15/2019 8/15/2019
5 additional Officers and Directors records available in full report.

Business Names
Business Name
biOasis Advanced Technologies Inc.
biOasis Technologies Inc.
BTI
W.R. Partners Ltd.

General Information
Outstanding Shares: 63,176,407 (As of 8/31/2019)
Stock Exchange: CVE
Fax Number: (604) 278-8785


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 18, 2019